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Abstract
Introduction There is sufficient evidence that blood group
related Lewis antigens are tumour-associated molecules. The
Lewisy and Lewisb antigens are complex carbohydrates that are
over-expressed by breast, lung, colon and ovarian cancers. The
SC101 mAb is a unique Lewisy/b binding antibody that binds to
native and extended Lewisy and Lewisb haptens, displaying no
cross reactivity with H type 1, H type 2, Lewisx or normal blood
group antigens.
Methods Immunohistochemical detection of Lewisy/b  was
performed on 660 formalin-fixed, paraffin embedded breast
tumour specimens using a streptavidin-biotin peroxidase
technique. Tissue from these patients had previously been
included in tissue microarrays. This cohort comprises a well
characterized series of patients with primary operable breast
cancer diagnosed between 1987 and 1992, obtained from the
Nottingham Tenovus Primary Breast Carcinoma Series. This
includes patients 70 years of age or less, with a mean follow up
of 7 years.
Results Of the breast carcinomas, 370 of 660 (56%) were
negative for Lewisy/b expression, 110 (17%) cases showed a
low level of expression (<25% of positive cells) and only 54
cases (8%) showed extensive expression of Lewisy/b (>75% of
positive cells). We found significant positive associations
between histological grade (p < 0.001), Nottingham Prognostic
Index (p = 0.016), tumour type (p = 0.007) and the level of
Lewis  y/b  expression. There was a significant correlation
between the proportion of Lewisy/b positive tumour cells and
survival in lymph-node negative patients (p = 0.006).
Conclusion The unique epitope recognised by SC101 mAb on
Lewisy/b  hapten is over-expressed on breast tumour tissue
compared with normal breast. In this large series of invasive
breast cancers, higher expression of Lewisy/b was more often
found in high grade and poor prognosis tumours compared to
good prognosis cancers. Moreover, in lymph node negative
breast carcinomas, over-expression of Lewisy/b  hapten was
associated with significantly decreased patient survival.
Introduction
Blood group related antigens are frequently altered in associ-
ation with neoplastic transformation [1-3]. Lewis blood group
antigens Lewisa  and Lewisb, and their positional isomers
Lewisx and Lewisy, are carbohydrate antigens. Lewisy antigen
is a difucosylated oligosaccharide with the chemical structure
Fucα 1→ 2Galβ 1→ 4[Fucα 1→ 3]GlcNAcβ 1→ R, which
belongs to the A, B, H, Lewis blood group family. The Lewisy
antigen is expressed predominately during embryogenesis,
and in adults expression is restricted to granulocytes and epi-
thelial surfaces [4]. Over-expression of Lewisy has been shown
in the majority of cancer cells derived from epithelial tissues,
however, including breast, ovary, pancreas, prostate, colon
and non-small cell lung cancers [5], either at the plasma mem-
brane as a glycolipid or linked to surface receptors (e.g. of the
E-rb-B family) [6].
The SC101/29 mAb is a unique Lewisy/b binding antibody that
recognises both Lewisy and Lewisb haptens [7]. It shows no
cross reactivity with H type 1 or H type 2, Lewisx or normal
blood group antigens. This antibody binds strongly to a wide
range of tumour tissues, including colon, gastric and ovarian
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and it may also show strong reactivity with a range of normal
tissue expressing either Lewisy or Lewisb.
To our knowledge, there has been no previous study examin-
ing whether there is any prognostic significance of Lewisy/b
expression in breast carcinoma. It was, therefore, of interest to
determine the expression of Lewisy/b in a large series of breast
cancer tissue arrays using the SC101 mAb. Expression of
Lewisy/b was then associated with clinicopathological parame-
ters and patient outcomes.
Materials and methods
Patients and tumour characteristics
The study group consisted of 660 primary operable invasive
breast carcinomas from patients aged 27 to 70 years (median
54 years) diagnosed from 1987 to 1992 and obtained from
the Nottingham Tenovus Primary Breast Carcinoma Series.
Patient characteristics, including age and menopausal status,
along with information on local, regional and distant recur-
rence and survival were retrieved from a prospectively main-
tained database. Patients and tumour characteristics are
shown in Table 1. Patients were followed up at 3 month inter-
vals initially, then every 6 to 12 months for a median period of
83 months, with a mean survival of 77 months (1 to 151
months). Ethical approval was granted by the Nottingham
Research Ethics Committee.
This is a well characterized series of primary operable breast
cancers treated in a uniform manner, and has been used to
study a wide range of potential prognostic factors and mark-
ers. Tumour characteristics, including histological grade [8],
tumour type [9], vascular invasion [10], menopausal status
[11], tumour size, lymph node stage and Nottingham Prognos-
tic Index [12] are routinely assessed and recorded in a pro-
spectively maintained database. The Nottingham Prognostic
Index (NPI) score was calculated for each patient based on the
following equation:
NPI = 0.2 × tumour size (cm) + grade (1–3) + lymph node
stage (1–3)
Table 1
Patient and tumour characteristics
Tumour and patient characteristics Proportion
Alive 86% (570)
Dead (of breast cancer) 14% (90)
Age (years)
<40 9%(58)
41–50 29%(192)
51–60 33% (221)
>61 29% (189)
Menopausal statusa
Premenopausal 36% (227/623)
Postmenopausal 64% (396/623)
Histological grade
Grade 1 20% (135)
Grade 2 33% (215)
Grade 3 47% (310)
Lymph node status
Negative 65% (427)
Positive 35% (233)
Nottingham Prognostic Indexa
Good 35%(226/638)
Moderate 52%(332/638)
Poor 13%(80/632)
Tumour histological typeb
Group 1 5% (32/647)
Group 2 22% (142/647)
Group 3 12% (78/647)
Group 4 61% (395/647)
Vascular invasiona
None or probable 69% (444/643)
Definite 31% (199/643)
Distant metastases
Absent 85%(559)
Present 15% (101)
Any recurrence
Absent 74% (488)
Present 26% (172)
Regional recurrence (axillary lymph node)
Absent 91% (598)
Present 9% (62)
Local recurrence (in the breast)
Absent 90% (591)
Present 10% (69)
aPercentage of total number of recorded cases. bTumour sections 
were classified into four prognostic type groups as previously 
described [26]: 1, excellent prognosis type (>80% 10 year survival) 
includes tubulo-lobular, tubular, mucinous and invasive cribriform 
carcinoma; 2, good types (60% to 80% 10 year survival) includes 
tubular mixed, mixed ductal with special type and alveolar lobular 
carcinoma; 3, moderate prognosis types (50% to 60% 10 year 
survival) includes classical lobular, medullary, atypical medullary and 
lobular mixed carcinoma; 4, poor prognosis types (≤  50% 10 year 
survival) includes ductal/NST, solid lobular, mixed ductal and lobular 
carcinoma.
Table 1 (Continued)
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This index predicts survival of patients with invasive breast
cancer and is used clinically to define three groups with either
a good (NPI =≤  3.4), moderate (3.41 < NPI ≤  5.4) or poor (NPI
> 5.4) prognosis according to the score obtained. Patient
management was based on tumour characteristics by NPI and
hormone receptor status. Patients with an NPI score ≤  3.4
received no adjuvant therapy, those with a NPI score >3.4
received tamoxifen if estrogen receptor (ER) positive (±
Zoledex if pre-menopausal) or classical cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) if ER negative and fit
enough to tolerate chemotherapy.
Construction of the tissue microarray blocks
At the time of resection, all tumours were managed in a stand-
ardised fashion, with immediate incision and fixation in neutral
buffered formalin to minimize any diffusion problems, followed
by processing through to embedding in paraffin wax. Breast
cancer tissue microarrays were prepared as described previ-
ously [13]. Microarray samples with a diameter of 0.6 mm were
punched from selected regions of each 'donor' block using a
manual Tissue Arrayer (Beecher Instruments, Sun Prairie, WI,
USA), and precisely arrayed into a new recipient paraffin
block. These tissue microarray blocks were constructed in trip-
licate, at a density of 100 cores per block.
Immunohistochemistry
The SC101 mAb binds to native and extended Lewisy and
Lewisb haptens [7]. Tissue microarray sections 4 µm thick
were cut and immunohistochemical staining was performed
using a strepavidin-biotin complex (ABC) method as
described previously [14]. Microwave pre-treatment was per-
formed in citrate buffer (pH 6.0) for 10 minutes at high power
followed by 10 minutes at low power to retrieve antigenicity.
The primary antibody SC101 was incubated on the slides for
1 h, at an optimal dilution found to be 1:1000 (stock concen-
tration 1.1 mg/ml). Negative controls, consisting of normal
swine serum instead of primary antibody, confirmed the specif-
icity of the staining. Sections from a colon carcinoma previ-
ously determined to express Lewisy/b were used as positive
control.
Evaluation of immunostaining
All immunostained tissue arrays were evaluated using a semi-
quantitative system (by ZM) after a series was examined on a
double-headed microscope blinded to patients' outcome and
other clinical and pathological parameters. The obtained
results were confirmed by two observers (ZM and IOE) using
a multi-headed microscope and, in difficult cases, a consensus
was achieved. Two features were assessed, the intensity of
staining and the percentage of cells stained. The intensity of
the immunostaining was classified into four categories: 0, no
immunostaining present (as shown in Fig. 1); 1, weak immu-
nostaining (Fig. 2); 2, moderate immunostaining (Fig. 3); and
3, strong immunostaining (Fig. 4). The percentage of positive
cells at each intensity was also assessed semi-quantitatively,
then classified into four groups as 1 (<25% positive cells), 2
(25% to 50% positive cells), 3 (51% to 75% positive cells) or
4 (>75% positive cells). In addition, the histochemical score
(H score) of immunoreactivity was obtained by multiplying the
intensity and percentage scores [15]. The histochemical
scores were subgrouped into three groups of equal range for
analysis, and a score of <100 was considered weak, 100 to
200 as moderate and 201 to 300 as strong.
Statistical analysis
Statistical analysis of data was performed using the SPSS
package (version 11 for Windows; SPSS, Chicago, IL, USA).
The significance of associations was determined by means of
Figure 1
Tissue microarray core demonstrating tumour with absent Lewisy/b  expression Tissue microarray core demonstrating tumour with absent Lewisy/b 
expression. Fifty-six percent of breast tumours were entirely negative for 
Lewisy/b expression using SC101 monoclonal antibody.
Figure 2
Tissue microarray core demonstrating tumour with weak Lewisy/b  expression Tissue microarray core demonstrating tumour with weak Lewisy/b 
expression. Seventy percent of breast tumours showed weak expres-
sion of Lewisy/b using SC101.Breast Cancer Research    Vol 7 No 5    Madjd et al.
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the Pearson R test and/or Pearson chi-square tests. To give
sizes of effect and to look at the independence of effects, the
percentage of Lewisy/b positive cells reclassified as a binary
outcome (high, >25% positive cells; low, <25% positive cells)
and effects of clinicopathological parameters were assessed
using multiple logistic regression to give adjusted odds ratios
and 95% confidence intervals.
In survival analysis, Kaplan-Meier curves were derived and the
statistical significance of differences in survival between
groups with different Lewisy/b  expression was determined
using the log-rank test. Survival was censored if the patients
were still alive at the time of data analysis, or at the time of
death for patients who died from an unrelated cause. Multivar-
iate Cox regression analysis was used to evaluate the
independent prognostic effect of variables on overall survival.
P-values of <0.05 were identified as statistically significant.
Results
Level of expression of Lewisy/b on breast carcinomas
Of the breast carcinomas, 370 out of 660 (56%) were entirely
negative for Lewisy/b expression (Fig. 1). A variable percentage
of positively staining tumour cells was observed among the
remaining 290 breast carcinomas; 110 (17%) cases showed
a low level of expression (<25% of positive cells) and only 54
cases (8%) showed extensive expression of Lewisy/b (>75%
of positive cells) on the cell membrane (Table 2). The staining
observed was predominantly localised to the cell membrane
and cytoplasm. No nuclear staining was observed.
Similarly, with regard to the intensity of staining, 17% (106)
showed weak expression of Lewisy/b, whereas 89 (13%) and
95 (14%) of cases showed moderate and strong staining,
respectively (Figs 2, 3, 4; Table 3).
Association of Lewisy/b expression with 
clinicopathological characteristics
A frequency histogram for the percentage of positive cells
stained demonstrated that the mean value was 25%. This was
therefore chosen as an appropriate cut-off for subsequent
analysis (data not shown). Tumours were therefore divided
Figure 3
Tissue microarray core demonstrating tumour with moderate Lewisy/b  expression Tissue microarray core demonstrating tumour with moderate Lewisy/b 
expression. Thirteen percent of tumours showed moderate expression 
of Lewisy/b.
Figure 4
Tissue microarray core demonstrating tumour with strong Lewisy/b  expression Tissue microarray core demonstrating tumour with strong Lewisy/b 
expression. Fourteen percent of tumours demonstrated strong expres-
sion of Lewisy/b.
Table 2
Percentage of cells showing immunoreactivity of SC101
Percentage of SC101 positive cells % of tumours
0% (no staining) 56 (n = 370)
1% to 25% 17 (n = 110)
25% to 50% 11 (n = 71)
5% to 75% 8 (n = 55)
>75% 8 (n = 54)
Total 660
Table 3
Intensity of SC101 expression
Immunohistochemical score % of tumours
None 56 (n = 370)
Weak 16 (n = 106)
Moderate 13 (n = 89)
Strong 15 (n = 95)
Total 660Available online http://breast-cancer-research.com/content/7/5/R780
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into those with <25% versus those with >25% positive cells
stained based on the distribution of staining results.
A significant positive relationship was found between the per-
centage of Lewisy/b  positive tumour cells and histological
grade of invasive tumours (p < 0.001; Table 4); a higher per-
centage of Lewisy/b positive tumour cells were identified more
frequently in histological grade 3 tumours compared to grade
1 lesions. The odds ratio for higher percentage of Lewisy/b in
those with a poor histological grade compared with those with
a well differentiated tumour was 2.509 (95% confidence inter-
val, 1.51 to 4.16) (Table 5).
A higher percentage of positive tumour cells was also identi-
fied more frequently in tumours from patients in the poor
prognosis NPI group (NPI > 5.4) compared with those in the
good prognosis group (NPI ≤  3.4, p < 0.016), with an odds
ratio of 1.99 (1.13 to 3.5) (Table 5). In addition, a higher pro-
portion of Lewis y/b positive tumour cells was seen more fre-
quently in poor prognosis tumour types (ductal/ NST (No
Table 4
Association of Lewisy/b expression with clinicopathological characteristics (chi-square test)
Prognostic factors Cut-off points Intensity of staining (p-value) Percentage of positive cells (p-value)
Age (years; median 56) <40, 41–50, 51–60, >60 0.011 0.014
Menopausal status Pre- or post-menopausal 0.547 0.917
Histological grade Well, moderate, poor differentiated 0.009 <0.001
Lymph node (LN) stage LN -/ LN+ 0.368 0.419
Tumour size (mm) <10, 11–20, 21–30, 31–40, 41–50 0.594 0.884
Nottingham Prognostic Index Good, moderate, or poor 0.151 0.016
Tumour type 1, 2, 3 or 4 0.093 0.007
Vascular invasion None or definite 0.293 0.316
Distant metastases Absent or present 0.515 0.532
Any recurrence Absent or present 0.533 0.743
Local recurrence Absent or present 0.775 0.908
Regional recurrence Absent or present 0.314 0.278
Table 5
Logistic regression analysis of percentage of Lewisy/b positive cellsa
Prognostic factors Odds ratios (95% CI) Test for trend (linear by linear)
Histological grade <0.001
Well 1
Moderate 1.51 (0.87–2.61)
Poor 2.50 (1.51–4.16)
Nottingham Prognostic Index 0.016
Good 1
Moderate 1.63 (1.09–2.44)
Poor 1.99 (1.13–3.50)
Tumour type 0.007
Excellent 1
Good 2.03 (0.66–6.23)
Moderate 2.25 (0.701–7.25)
Poor 3.12 (1.07–9.11)
aPositive cells were categorized into two groups, high (<25%) and low (>25%). CI, confidence interval.Breast Cancer Research    Vol 7 No 5    Madjd et al.
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special type)), solid lobular, lobular mixed or mixed NST and
lobular cancers) compared to the excellent prognosis tumour
types (tubulo-lobular, tubular, mucinous and invasive cribri-
form) (p < 0.007), with an odds ratio of 3.12 (1.07 to 9.11)
(Table 5).
There was a positive association between the observed inten-
sity of expression of Lewisy/b and histological tumour grade (p
= 0.009). No association was found, however, between
intensity of expression and NPI or tumour type. Similarly, we
could not find any association between either intensity of
expression or the percentage of positive cells and the vascular
invasion status, local recurrence, lymph node stage or meno-
pausal status (Table 4).
Survival analysis
Kaplan-Meier analysis of this cohort of breast cancer patients,
with mean follow-up of 7 years, did not demonstrate significant
differences in the overall survival between patients with a low
percentage of Lewisy/b positive cells (<25%) versus patients
with >25% positive tumour cells in the cohort as a whole (Fig.
5). On subgroup analysis, however, a significant correlation (p
= 0.006) was identified between the proportion of Lewisy/b
positive tumour cells and survival in lymph-node negative
patients (Fig. 6). Analysis using the log-rank test showed that
in these lymph-node negative tumours (n = 430), patients with
a low percentage of Lewisy/b positive cells (<25% positive
cells, n = 315) have significantly longer survival times than
patients with >25% positive tumour cells (n = 115, p =
0.006).
In contrast, there was no significant association between the
intensity of Lewisy/b expression and overall survival between
the patient group with no expression of Lewisy/b versus posi-
tive tumours (weak, moderate or strong staining) in the cohort
as a whole (log rank = 0.667), or on subgroup analysis in
lymph-node negative patients (log rank = 0.140).
Multivariate analysis, including the factors of tumour size,
nodal status, tumour grade and Lewisy/b expression showed
that tumour size, tumour grade and nodal status were inde-
pendent prognostic parameters, whereas Lewisy/b expression
was not an independent prognostic marker in this patient
cohort.
Discussion
Blood group related antigens are frequently altered in associ-
ation with neoplastic transformation in many organs. This study
Figure 5
Correlation between the percentage of Lewisy/b positive tumour cells  and overall survival (n = 660) Correlation between the percentage of Lewisy/b positive tumour cells 
and overall survival (n = 660). Kaplan-Meier survival analysis. Compari-
son of breast cancer patients with a low percentage of Lewisy/b positive 
cells (blue curve: <25% positive cells, n = 480), and patients with 
>25% positive tumour cells (green curve: n = 180, p = 0.091).
Figure 6
Percentage of Lewisy/b positive cells and overall survival in node-nega- tive breast cancer patients (n = 430) Percentage of Lewisy/b positive cells and overall survival in node-nega-
tive breast cancer patients (n = 430). Kaplan-Meier analysis showed 
that patients with a low percentage of Lewisy/b positive cells (blue 
curve: <25% positive cells, n = 315) have significantly longer survival 
times than patients with >25% positive tumour cells (green curve: n = 
115, p = 0.006).Available online http://breast-cancer-research.com/content/7/5/R780
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illustrates the prognostic and potential predictive value of
Lewisy/b expression in a large series of 660 patients with inva-
sive breast carcinoma. Forty-four percent of cases demon-
strated Lewisy/b  expression, with eight percent showing
extensive expression. A higher percentage of Lewisy/b expres-
sion was significantly correlated with histological grade, NPI
and histological tumour type group and, in lymph-node nega-
tive patients, overall survival decreased with increasing level of
Lewisy/b expression.
There are few previous reports of blood group antigens in rela-
tion to prognosis from breast cancer. Our results are in
concordance with a previous study, however, in which higher
expression of Lewisa and Lewisb was observed in lymph node
negative tumours than in lymph node positive tumours, and
higher expression of Lewisb was seen in stage T4 than in stage
T1 tumours, suggesting that the expression of sialosyl-Lewisb
and Lewisa antigens in breast cancer may predict metastases
to lymph nodes [16]. A positive correlation between Lewisy
expression and a poor prognosis has also been shown for
superficial oesophageal carcinomas [17].
Lewisy and Lewisb are expressed on both glycolipids and glyc-
oproteins [6,18]. It has been shown that an antibody, ABL-
364, recognising Lewisy can inhibit Erb-B signalling by rerout-
ing these receptors to a submembrane compartment from
which they rapidly recycle to the cell surface [19]. A previous
study on this series of breast tissue arrays has shown that
expression of the epidermal growth factor receptor (Erb-B1)
was significantly associated with a high histological grade,
high NPI score, negative ER status, larger tumour size, the
development of distant metastases and death from cancer.
We have also demonstrated that c-erbB-2 expression
independently predicted for poor overall survival in this popu-
lation of breast cancer patients [20]. There was no associa-
tion, however, between Erb-B1 expression and Lewisy
expression in this group of tumours.
Lewisy can be up-regulated in response to cellular stress.
Indeed, up-regulation of Lewisy in response to chemothera-
peutic stress, and in particular to the chemotherapeutic agent
5-fluorouracil, has been previously reported [21]. In early stage
breast cancer, expression of Lewisy/b may, therefore, be a
marker of aggressive or stressed tumours.
A range of Lewisy antibodies have been identified, but these
consistently cross react with Lewisx and H type 2 structures.
This can lead to undesirable cross reactivity with normal tis-
sues and subsequent toxicity in clinical trials. In a phase I study
of the murine BR55-2 anti-Lewisy antibody, which cross reacts
with H antigen in breast cancer patients, haematuria occurred
in 6/12 patients and diarrhoea in 2/9 patients, with only tran-
sient reductions in skin lesions seen in 3 patients [22]. A chi-
meric BR-96-doxorubicin conjugate has also been evaluated
in patients with a range of advanced cancers. BR-96 cross-
reacts with B hapten and gastrointestinal binding was found to
be dose limiting [23]. Finally, the Lewisy specific humanised
antibody 3S193 has shown good selectivity in binding studies
and is about to enter phase I clinical trials [24]. Lewisy has also
been suggested as a target for cancer vaccines; however,
immunising with synthetic Lewisy generated carbohydrate spe-
cific antibodies but they failed to bind to tumour cells. In con-
trast, MMA383 is an anti-idiotypic antibody that mimics Lewisy
and stimulates good antibody responses. It has been human-
ised [25] and will shortly enter clinical trials.
Conclusion
Analysis of Lewisy/b expression in early stage breast cancer
patients may aid selection of patients for more aggressive
chemotherapy, as tumours with a high percentage of cells
expressing Lewisy/b  appear to have a significantly greater
chance of disease progression. This may also eventually allow
stratification of patients for mAb therapy directed against
these carbohydrate antigens; however, specific antibodies
that directly induce cell killing but do not cross react with H or
B blood groups first need to be selected. SC101/29 is a
promising candidate and is currently being humanised for clin-
ical trials.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ZM and NFSW carried out the immunohistochemistry, scored
the staining, analyzed the data and drafted the manuscript. TP
made the SC101 primary antibody. LGD, IOE and IS designed
the study and provided the tissue microarray. All authors were
responsible for interpreting the results and drafting the article.
All authors read and approved the final manuscript.
Acknowledgements
The authors thank Mrs Claire Paish and Mr John Ronan for their techni-
cal advice. This work was supported by a grant from the CRUK.
References
1. Wiley EL, Mendelsohn G, Eggleston JC: Distribution of carci-
noembryonic antigens and blood group substances in adeno-
carcinoma of the colon.  Lab Invest 1981, 44:507-513.
2. Inoue M, Nakayama M, Tanizawa O: Altered expression of Lewis
blood group and related antigens in fetal, normal adult and
malignant tissues of the uterine endometrium.  Virchows Arch
A Pathol Anat Histopathol 1990, 416:221-228.
3. Inoue M, Sasagawa T, Saito J, Shimizu H, Ueda G, Tanizawa O,
Nakayama M: Expression of blood group antigens A, B, H,
Lewis-a, and Lewis-b in fetal, normal, and malignant tissues of
the uterine endometrium.  Cancer 1987, 60:2985-2993.
4. Dettke M, Palfi G, Loibner H: Activation-dependent expression
of the blood group-related lewis Y antigen on peripheral blood
granulocytes.  J Leukoc Biol 2000, 68:511-514.
5. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE: Highly
tumor-reactive, internalizing, mouse monoclonal antibodies to
Le(y)-related cell surface antigens.  Cancer Res 1990,
50:2183-2190.
6. Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L, Das M: Pres-
ence of tumor-associated antigens in epidermal growth factor
receptors from different human carcinomas.  Cancer Res
1987, 47:2531-2536.Breast Cancer Research    Vol 7 No 5    Madjd et al.
R787
7. Durrant LG, Singhal A, Jacobs E, Price MR: Development of sec-
ond generation monoclonal antibodies recognising Lewisy/b
antigen by anti-idiotypic immunisation.  Hybridoma 1993,
12:647-660.
8. Elston CW, Ellis IO: Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer:
experience from a large study with long-term follow-up.  His-
topathology 1991, 19:403-410.
9. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW:
Pathological prognostic factors in breast cancer. II. Histologi-
cal type. Relationship with survival in a large study with long-
term follow-up.  Histopathology 1992, 20:479-489.
10. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW:
Pathological prognostic factors in breast cancer. III. Vascular
invasion: relationship with recurrence and survival in a large
study with long-term follow-up.  Histopathology 1994,
24:41-47.
11. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP,
Blamey RW, Haybittle JL: Confirmation of a prognostic index in
primary breast cancer.  Br J Cancer 1987, 56:489-492.
12. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham
Prognostic Index in primary breast cancer.  Breast Cancer Res
Treat 1992, 22:207-219.
13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P,
Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tis-
sue microarrays for high-throughput molecular profiling of
tumor specimens.  Nat Med 1998, 4:844-847.
14. Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE:
Loss of CD55 is associated with aggressive breast tumors.
Clin Cancer Res 2004, 10:2797-2803.
15. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr:
Estrogen receptor analyses. Correlation of biochemical and
immunohistochemical methods using monoclonal antirecep-
tor antibodies.  Arch Pathol Lab Med 1985, 109:716-721.
16. Steplewska-Mazur K, Gabriel A, Zajecki W, Wylezol M, Gluck M:
Breast cancer progression and expression of blood group-
related tumor-associated antigens.  Hybridoma 2000,
19:129-133.
17. Tauchi K, Kakudo K, Machimura T, Makuuchi H, Mitomi T: Immu-
nohistochemical studies of blood group-related antigens in
human superficial esophageal carcinomas.  Cancer 1991,
67:3042-3050.
18. Garrigues J, Anderson J, Hellstrom KE, Hellstrom I: Anti-tumor
antibody BR96 blocks cell migration and binds to a lysosomal
membrane glycoprotein on cell surface microspikes and ruf-
fled membranes.  J Cell Biol 1994, 125:129-142.
19. Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H,
Mudde GC, Freissmuth M, Sexl V: Antibodies directed against
Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB
receptors.  Cancer Res 2004, 64:1087-1093.
20. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS,
Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression and
co-expression of the members of the epidermal growth factor
receptor (EGFR) family in invasive breast carcinoma.  Br J
Cancer 2004, 91:1532-1542.
21. Flieger D, Hoff AS, Sauerbruch T, Schmidt-Wolf IG: Influence of
cytokines, monoclonal antibodies and chemotherapeutic
drugs on epithelial cell adhesion molecule (EpCAM) and
LewisY antigen expression.  Clin Exp Immunol 2001, 123:9-14.
22. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs
C, Young L, Healey D, Onetto N, Slichenmyer W: Randomized
phase II study of BR96-doxorubicin conjugate in patients with
metastatic breast cancer.  J Clin Oncol 1999, 17:478-484.
23. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D,
Daniel CR, LeBherz D, Brewer H, Onetto N, et al.: Phase I trial of
the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in
patients with lewis Y-expressing epithelial tumors.  J Clin
Oncol 2000, 18:2282-2292.
24. Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE,
Stockert E, Richards EC, Carr FJ, Harris WJ, et al.: Construction,
production, and characterization of humanized anti-Lewis Y
monoclonal antibody 3S193 for targeted immunotherapy of
solid tumors.  Cancer Res 2000, 60:3254-3261.
25. Co MS, Baker J, Bednarik K, Janzek E, Neruda W, Mayer P, Plot R,
Stumper B, Vasquez M, Queen C, et al.: Humanized anti-Lewis
Y antibodies: in vitro properties and pharmacokinetics in rhe-
sus monkeys.  Cancer Res 1996, 56:1118-1125.
26. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW,
Blamey RW, Robertson JF, Ellis IO: Pathological prognostic fac-
tors in breast cancer. IV: Should you be a typer or a grader? A
comparative study of two histological prognostic features in
operable breast carcinoma.  Histopathology 1995, 27:219-226.